{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:10:16Z","timestamp":1780096216735,"version":"3.54.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The management of stage III melanoma has undergone profound change with the advent of effective systemic therapies and the growing use of neoadjuvant immunotherapy. This paper highlights the issues raised and points discussed during the Great Debates session at the 2024 SSO Conference in Atlanta, focusing on the necessity of therapeutic lymph node dissection (TLND) after index lymph node (ILN) surgery.<\/jats:p>","DOI":"10.1245\/s10434-025-18163-2","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:43:07Z","timestamp":1756496587000},"page":"8930-8936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Melanoma Great Debate: Targeted Versus Complete Nodal Dissection Following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold Off on Continued De-Escalation of Surgery?"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-6935","authenticated-orcid":false,"given":"Alexander","family":"van Akkooi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-3895","authenticated-orcid":false,"given":"Charlotte","family":"Ariyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-235X","authenticated-orcid":false,"given":"Marc","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"18163_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599\u2013609.","journal-title":"N Engl J Med."},{"key":"18163_CR2","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med."},{"key":"18163_CR3","first-page":"2200214","volume":"1","author":"AMM Eggermont","year":"2022","unstructured":"Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid Massachusetts Med Soc. 2022;1:2200214.","journal-title":"NEJM Evid Massachusetts Med Soc"},{"key":"18163_CR4","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38:3937\u201346.","journal-title":"J Clin Oncol."},{"key":"18163_CR5","doi-asserted-by":"publisher","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 Sep;377:1824\u20131835 [cited 2017 Oct 24]. Available at: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1709030","DOI":"10.1056\/NEJMoa1709030"},{"key":"18163_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Kirkwood JM, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383:1139\u201348.","journal-title":"N Engl J Med."},{"key":"18163_CR7","unstructured":"Center for Drug Evaluation, Research. FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations. US Food and Drug Administration; 2024 [cited 2024 Aug 26]. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations"},{"key":"18163_CR8","unstructured":"Center for Drug Evaluation, Research. FDA approves nivolumab for adjuvant treatment of Stage IIB\/C melanoma. US Food and Drug Administration; 2023 [cited 2024 Aug 26]. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-adjuvant-treatment-stage-iibc-melanoma"},{"key":"18163_CR9","unstructured":"Center for Drug Evaluation, Research. FDA approves pembrolizumab for adjuvant treatment of melanoma. US Food and Drug Administration; 2024 [cited 2024 Aug 26]. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adjuvant-treatment-melanoma"},{"key":"18163_CR10","unstructured":"Center for Drug Evaluation, Research. FDA grants regular approval to nivolumab for adjuvant treatment of melanoma. US Food and Drug Administration; 2024 [cited 2024 Aug 26]. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-nivolumab-adjuvant-treatment-melanoma"},{"key":"18163_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757\u201367.","journal-title":"Lancet Oncol."},{"key":"18163_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","volume":"27","author":"DM Bello","year":"2020","unstructured":"Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. 2020;27:15\u201321.","journal-title":"Ann Surg Oncol."},{"key":"18163_CR13","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","volume":"17","author":"MB Faries","year":"2010","unstructured":"Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the multicenter selective lymphadenectomy trial (I). Ann Surg Oncol Springer. 2010;17:3324\u20139.","journal-title":"Ann Surg Oncol. Springer"},{"key":"18163_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 0102\/TROG 0201): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1049\u201360.","journal-title":"Lancet Oncol."},{"key":"18163_CR15","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178\u201388.","journal-title":"Nat Med."},{"key":"18163_CR16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391:1696\u2013708.","journal-title":"N Engl J Med."},{"key":"18163_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, et al. Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323.","journal-title":"N Engl J Med."},{"key":"18163_CR18","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Melanoma: Cutaneous Version 2.2025 [cited 2025 Jul 14]. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"18163_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fonc.2012.00125","volume":"2","author":"U Veronesi","year":"2012","unstructured":"Veronesi U, Stafyla V, Luini A, Veronesi P. Breast cancer: from \u201cmaximum tolerable\u201d to \u201cminimum effective\u201d treatment. Frontiers in Oncology. 2012;2:125.","journal-title":"Frontiers in Oncology"},{"key":"18163_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJM198107023050102","volume":"305","author":"U Veronesi","year":"1981","unstructured":"Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305:6\u201311.","journal-title":"N Engl J Med."},{"key":"18163_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1056\/NEJM197709222971202","volume":"297","author":"U Veronesi","year":"1977","unstructured":"Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627\u201330.","journal-title":"N Engl J Med."},{"key":"18163_CR22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1611299.","journal-title":"N Engl J Med."},{"key":"18163_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med."},{"key":"18163_CR24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med."},{"key":"18163_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41:517\u201327.","journal-title":"J Clin Oncol."},{"key":"18163_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u201361.","journal-title":"Nat Med."},{"key":"18163_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611:155\u201360.","journal-title":"Nature."},{"key":"18163_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19:181\u201393.","journal-title":"Lancet Oncol."},{"key":"18163_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24:1649\u201354.","journal-title":"Nat Med."},{"key":"18163_CR30","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20:948\u201360.","journal-title":"Lancet Oncol."},{"key":"18163_CR31","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","volume":"15","author":"TJ Hieken","year":"2024","unstructured":"Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable stage III melanoma: the phase II NeoACTIVATE trial. Nat Commun. 2024;15:1430.","journal-title":"Nat Commun."},{"key":"18163_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25:454\u201361.","journal-title":"Nat Med."},{"key":"18163_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/bjs.11168","volume":"106","author":"B Schermers","year":"2019","unstructured":"Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br J Surg. 2019;106:519\u201322.","journal-title":"Br J Surg."},{"key":"18163_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","volume":"157","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg. 2022;157:335\u201342.","journal-title":"JAMA Surg."},{"key":"18163_CR35","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","volume":"378","author":"P Gillgren","year":"2011","unstructured":"Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, M\\a ansson-Brahme E, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378:1635\u201342.","journal-title":"Lancet."},{"key":"18163_CR36","first-page":"101","volume":"8","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong S-J, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1\u20134 mm melanomas. Ann Surg Oncol. 2001;8:101\u20138.","journal-title":"Ann Surg Oncol."},{"key":"18163_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/archsurg.1991.01410280036004","volume":"126","author":"U Veronesi","year":"1991","unstructured":"Veronesi U, Cascinelli N. Narrow excision (1-cm margin) A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438\u201341.","journal-title":"Arch Surg."},{"key":"18163_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00000658-199609000-00002","volume":"224","author":"CM Balch","year":"1996","unstructured":"Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255.","journal-title":"Ann Surg."},{"key":"18163_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","volume":"34","author":"JM Versluis","year":"2023","unstructured":"Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34:420\u201330.","journal-title":"Ann Oncol."},{"key":"18163_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115141","volume":"214","author":"ILM Reijers","year":"2025","unstructured":"Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer. 2025;214:115141.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18163-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:41:09Z","timestamp":1760715669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18163-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["18163"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18163-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alexander van Akkooi has received honoraria from, or participated in a consultancy or advisory role for, Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Genmab, Menarini Silicon Biosystems, Merck Serono-Pfizer, MSD Merck, Neracare, Novartis, Pierre Fabre, Provectus, Replimune, Sanofi, Sirius Medical, SkylineDx, and 4SC, and has received research funding from Amgen, Merck Serono\u2013Pfizer, and SkylineDx. Charlotte Ariyan has received support from Iovance Biotherapeutics, Inc., Pfizer, Merck, Bristol Myers Squibb, and is a member of the Advisory Board for Replimune and Mural Oncology. Marc Moncrieff has no disclosures to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}